


Supplement Figure 1 The basic components of the deep neural network

Supplement Figure 2. The deep neural network was visualized using the "Netron" tool.

A. Visualization of deep neural network model 1; B. Visualization of deep neural network model 2.



| | Train set | | Test | P Valı | |
|-------------------|-----------|--------|--------|--------|---------|
| | N=7094 | % | N=3041 | % | i vaiut |
| Age at diagnosis | | | | | 0.145 |
| <40 | 810 | 11.42% | 313 | 10.29% | |
| 40-49 | 1232 | 17.37% | 519 | 17.07% | |
| 50-59 | 1971 | 27.78% | 885 | 29.10% | |
| 60-69 | 1846 | 26.02% | 837 | 27.52% | |
| 70-79 | 944 | 13.31% | 376 | 12.36% | |
| ≥ 80 | 291 | 4.10% | 111 | 3.65% | |
| Subtype | | | | | 0.630 |
| HR+/HER2- | 3373 | 47.55% | 1468 | 48.27% | |
| HR+/HER2+ | 1394 | 19.65% | 557 | 18.32% | |
| HR-/HER2+ | 796 | 11.22% | 347 | 11.41% | |
| HR-/HER2- | 1022 | 14.41% | 452 | 14.86% | |
| Unknown | 509 | 7.18% | 217 | 7.14% | |
| Race | | | | | 0.566 |
| White | 5221 | 73.60% | 2215 | 72.84% | |
| Black | 1069 | 15.07% | 490 | 16.11% | |
| Others | 766 | 10.80% | 318 | 10.46% | |
| Unknown | 38 | 0.54% | 18 | 0.59% | |
| Histological type | | | | | 0.548 |
| IDC | 5211 | 73.46% | 2231 | 73.36% | |
| ILC | 581 | 8.19% | 248 | 8.16% | |
| Mixed | 381 | 5.37% | 146 | 4.80% | |
| Others | 921 | 12.98% | 416 | 13.68% | |
| Marital status | | | | | 0.681 |
| Married | 3382 | 47.67% | 1449 | 47.65% | |
| Unmarried | 3396 | 47.87% | 1468 | 48.27% | |
| Unknown | 316 | 4.45% | 124 | 4.08% | |
| T stage | | | | | 0.347 |
| T1 | 686 | 9.67% | 288 | 9.47% | |
| T2 | 2045 | 28.83% | 844 | 27.75% | |
| Т3 | 1185 | 16.70% | 479 | 15.75% | |
| T4 | 2290 | 32.28% | 1028 | 33.80% | |

Supplement Table 1. Comparison of patient characteristics in the train and test sets of the

| Grade | | | | | 0.673 |
|-------------------------------|------|--------|------|--------|-------|
| I; Well differentiated | 369 | 5.20% | 151 | 4.97% | |
| II; Moderately differentiated | 2251 | 31.73% | 992 | 32.62% | |
| III/IV; Poorly differentiated | 3077 | 43.37% | 1286 | 42.29% | |
| Unknown | 1397 | 19.69% | 612 | 20.12% | |
| Median household income | | | | | 0.481 |
| (inflation adjusted) | | | | | 0.401 |
| <50,000\$ | 826 | 11.64% | 365 | 12.00% | |
| 50,000-59,999\$ | 1100 | 15.51% | 479 | 15.75% | |
| 60,000-69,999\$ | 2444 | 34.45% | 999 | 32.85% | |
| ≥70,000\$ | 2724 | 38.40% | 1198 | 39.39% | |
| Surgery | | | | | 0.434 |
| No | 5307 | 74.81% | 2298 | 75.57% | |
| Yes | 1787 | 25.19% | 743 | 24.43% | |
| Distant metastases | | | | | 0.135 |
| Bone only | 2322 | 32.73% | 1025 | 33.71% | |
| Liver only | 599 | 8.44% | 244 | 8.02% | |
| Lung only | 632 | 8.91% | 262 | 8.62% | |
| Brain only | 77 | 1.09% | 37 | 1.22% | |
| Bone+Liver | 702 | 9.90% | 263 | 8.65% | |
| Bone+Lung | 521 | 7.34% | 249 | 8.19% | |
| Bone+Brain | 117 | 1.65% | 37 | 1.22% | |
| Bone+Liver+Lung | 354 | 4.99% | 133 | 4.37% | |
| Liver+Lung | 149 | 2.10% | 69 | 2.27% | |
| Brain+Other | 360 | 5.07% | 186 | 6.12% | |
| Other metastases | 1261 | 17.78% | 533 | 17.53% | |

Brain+other: cases of brain metastases combined with other metastases except for the bone+brain, e.g. brain+liver etc. Other metastases: other cases of metastases than those listed in the table.

| | Train set | | Test | D X7-1 | |
|------------------------------|-----------|--------|-------|--------|---------|
| | N=1787 | % | N=743 | % | P Value |
| Age at diagnosis | | | | | 0.716 |
| <40 | 270 | 15.11% | 112 | 15.07% | |
| 40-49 | 368 | 20.59% | 155 | 20.86% | |
| 50-59 | 488 | 27.31% | 206 | 27.73% | |
| 60-69 | 410 | 22.94% | 183 | 24.63% | |
| 70-79 | 208 | 11.64% | 71 | 9.56% | |
| ≥ 80 | 43 | 2.41% | 16 | 2.15% | |
| Subtype | | | | | 0.515 |
| HR+/HER2- | 795 | 44.49% | 353 | 47.51% | |
| HR+/HER2+ | 389 | 21.77% | 140 | 18.84% | |
| HR-/HER2+ | 223 | 12.48% | 93 | 12.52% | |
| HR-/HER2- | 314 | 17.57% | 131 | 17.63% | |
| Unknown | 66 | 3.69% | 26 | 3.50% | |
| Race | | | | | 0.775 |
| White | 1313 | 73.48% | 542 | 72.95% | |
| Black | 260 | 14.55% | 115 | 15.48% | |
| Others | 208 | 11.64% | 85 | 11.44% | |
| Unknown | 6 | 0.34% | 1 | 0.13% | |
| Histological type | | | | | 0.056 |
| IDC | 1465 | 81.98% | 591 | 79.54% | |
| ILC | 97 | 5.43% | 51 | 6.86% | |
| Mixed | 123 | 6.88% | 42 | 5.65% | |
| Others | 102 | 5.71% | 59 | 7.94% | |
| Marital status | | | | | 0.579 |
| Married | 945 | 52.88% | 376 | 50.61% | |
| Unmarried | 768 | 42.98% | 335 | 45.09% | |
| Unknown | 74 | 4.14% | 32 | 4.31% | |
| T stage | | | | | 0.968 |
| T1 | 193 | 10.80% | 77 | 10.36% | |
| T2 | 650 | 36.37% | 277 | 37.28% | |
| T3 | 355 | 19.87% | 140 | 18.84% | |
| T4 | 533 | 29.83% | 226 | 30.42% | |
| Unknown | 56 | 3.13% | 23 | 3.10% | |
| Grade | | | | | 0.572 |
| I; Well differentiated | 79 | 4.42% | 33 | 4.44% | |
| ; Moderately differentiated | 577 | 32.29% | 261 | 35.13% | |
| II/IV; Poorly differentiated | 996 | 55.74% | 397 | 53.43% | |

Supplement Table 2. Comparison of patient characteristics in the train and test sets of the

| Unknown | 135 | 7.55% | 52 | 7.00% | |
|------------------------------|-------|--------|-------------|--------|-------|
| Median household income | | | | | 0.453 |
| (inflation adjusted) | | | | | 0.455 |
| <50,000\$ | 241 | 13.49% | 106 | 14.27% | |
| 50,000-59,999\$ | 312 | 17.46% | 119 | 16.02% | |
| 60,000-69,999\$ | 614 | 34.36% | 240 | 32.30% | |
| ≥70,000\$ | 620 | 34.70% | 278 | 37.42% | |
| Neoadjuvant systemic therapy | | | | | 0.837 |
| No | 885 | 49.52% | 372 | 50.07% | |
| Yes | 902 | 50.48% | 371 | 49.93% | |
| Distant metastases | | | | | 0.323 |
| Bone only | 730 | 40.85% | 327 | 44.01% | |
| Liver only | 223 | 12.48% | 91 | 12.25% | |
| Lung only | 222 | 12.42% | 82 | 11.04% | |
| Brain only | 23 | 1.29% | 9 | 1.21% | |
| Bone+Liver | 122 | 6.83% | 38 | 5.11% | |
| Bone+Lung | 81 | 4.53% | 45 | 6.06% | |
| Bone+Brain | 13 | 0.73% | 4 | 0.54% | |
| Bone+Liver+Lung | 44 | 2.46% | 13 | 1.75% | |
| Liver+Lung | 43 | 2.41% | 10 | 1.35% | |
| Brain+Other | 38 | 2.13% | 16 | 2.15% | |
| Other metastases | 248 | 13.88% | 108 | 14.54% | |
| | C 1 ' | 1. 1 | · · · · · · | | |

Brain+other: cases of brain metastases combined with other metastases except for the bone+brain, e.g. brain+liver etc. Other metastases: other cases of metastases than those listed in the table.

| | C | W | Ν | VS | S | С | N17 I |
|-------------------|--------|---------|-----------|---------|--------|------------------|--------------|
| | N=7605 | % | N=1273 | % | N=1257 | % | P Value |
| Age at diagnosis | | | | | | | <0.001 |
| <40 | 741 | 9.74% | 236 | 18.54% | 146 | 11.61% | |
| 40-49 | 1228 | 16.15% | 292 | 22.94% | 231 | 18.38% | |
| 50-59 | 2162 | 28.43% | 372 | 29.22% | 322 | 25.62% | |
| 60-69 | 2090 | 27.48% | 253 | 19.87% | 340 | 27.05% | |
| 70-79 | 1041 | 13.69% | 106 | 8.33% | 173 | 13.76% | |
| ≥ 80 | 343 | 4.51% | 14 | 1.10% | 45 | 3.58% | |
| Subtype | | | | | | | <0.001 |
| HR+/HER2- | 3693 | 48.56% | 532 | 41.79% | 625 | 49.72% | |
| HR+/HER2+ | 1422 | 18.70% | 307 | 24.12% | 222 | 17.66% | |
| HR-/HER2+ | 827 | 10.87% | 176 | 13.83% | 140 | 11.14% | |
| HR-/HER2- | 1029 | 13.53% | 227 | 17.83% | 218 | 17.34% | |
| Unknown | 634 | 8.34% | 40 | 3.14% | 52 | 4.14% | |
| Race | | | | | | | 0. |
| White | 5581 | 73.39% | 924 | 72.58% | 931 | 74.07% | |
| Black | 1184 | 15.57% | 182 | 14.30% | 193 | 15.35% | |
| Others | 791 | 10.40% | 163 | 12.80% | 130 | 10.34% | |
| Unknown | 49 | 0.64% | 4 | 0.31% | 3 | 0.24% | |
| Histological type | | | | | | | <0.001 |
| IDC | 5386 | 70.82% | 1072 | 84.21% | 984 | 78.28% | |
| ILC | 681 | 8.95% | 52 | 4.08% | 96 | 7.64% | |
| Mixed | 362 | 4.76% | 69 | 5.42% | 96 | 7.64% | |
| Others | 1176 | 15.46% | 80 | 6.28% | 81 | 6.44% | |
| Marital status | | | | | - | - | <0.001 |
| Married | 3510 | 46.15% | 666 | 52.32% | 655 | 52.11% | |
| Unmarried | 3761 | 49.45% | 555 | 43.60% | 548 | 43.60% | |
| Unknown | 334 | 4.39% | 52 | 4.08% | 54 | 4.30% | |
| T stage | 557 | 1.3770 | 52 | 1.0070 | JT | 1.5070 | <0.001 |
| T1 | 704 | 9.26% | 112 | 8.80% | 158 | 12.57% | |
| T2 | 1962 | 25.80% | 352 | 27.65% | 575 | 45.74% | |
| T2 T3 | 1169 | 15.37% | 271 | 21.29% | 224 | 43.74% 17.82% | |
| T4 | 2559 | 33.65% | 504 | 39.59% | 255 | 20.29% | |
| 14 Unknown | 1211 | | 304 34 | | | 3.58% | |
| | 1211 | 15.92% | 54 | 2.67% | 45 | 3.38%0 | ~0.001 |
| N stage | 1406 | 10 750/ | 150 | 11 0407 | 212 | 16 070/ | <0.001 |
| N0 | 1426 | 18.75% | 152 | 11.94% | 212 | 16.87% | |
| N1 | 3811 | 50.11% | 574 | 45.09% | 421 | 33.49% | |
| N2 | 597 | 7.85% | 221 | 17.36% | 279 | 22.20% | |

Supplement Table 3: Baseline characteristics of de novo metastatic breast cancer (dnMBC) patients included from SEER data cohort

| Unknown | 659 | 8.67% | 18 | 1.41% | 32 | 2.55% | |
|-------------------------------|------|--------|-----|--------|-----|--------|--------|
| Grade | | | | | | | <0.001 |
| I; Well differentiated | 408 | 5.36% | 49 | 3.85% | 63 | 5.01% | |
| II; Moderately differentiated | 2405 | 31.62% | 428 | 33.62% | 410 | 32.62% | |
| III/IV; Poorly differentiated | 2970 | 39.05% | 690 | 54.20% | 703 | 55.93% | |
| Unknown | 1822 | 23.96% | 106 | 8.33% | 81 | 6.44% | |
| Median household income | | | | | | | -0.001 |
| (inflation adjusted) | | | | | | | <0.001 |
| <50,000\$ | 844 | 11.10% | 145 | 11.39% | 202 | 16.07% | |
| 50,000-59,999\$ | 1148 | 15.10% | 206 | 16.18% | 225 | 17.90% | |
| 60,000-69,999\$ | 2589 | 34.04% | 462 | 36.29% | 392 | 31.19% | |
| ≥70,000\$ | 3024 | 39.76% | 460 | 36.14% | 438 | 34.84% | |
| Radiotherapy | | | | | | | <0.001 |
| None/unknown | 5438 | 71.51% | 513 | 40.30% | 766 | 60.94% | |
| Yes | 2167 | 28.49% | 760 | 59.70% | 491 | 39.06% | |
| Distant metastases | | | | | | 0.00% | <0.001 |
| Bone only | 2290 | 30.11% | 546 | 42.89% | 511 | 40.65% | |
| Liver only | 529 | 6.96% | 152 | 11.94% | 162 | 12.89% | |
| Lung only | 590 | 7.76% | 159 | 12.49% | 145 | 11.54% | |
| Brain only | 82 | 1.08% | 12 | 0.94% | 20 | 1.59% | |
| Bone+Liver | 805 | 10.59% | 67 | 5.26% | 93 | 7.40% | |
| Bone+Lung | 644 | 8.47% | 53 | 4.16% | 73 | 5.81% | |
| Bone+Brain | 140 | 1.84% | 5 | 0.39% | 12 | 0.95% | |
| Bone+Liver+Lung | 430 | 5.65% | 25 | 1.96% | 32 | 2.55% | |
| Liver+Lung | 165 | 2.17% | 23 | 1.81% | 30 | 2.39% | |
| Brain+Other | 492 | 6.47% | 19 | 1.49% | 35 | 2.78% | |
| Other metastases | 1438 | 18.91% | 212 | 16.65% | 144 | 11.46% | |

Brain+other: cases of brain metastases combined with other metastases except for the bone+brain, e.g. brain+liver etc. Other metastases: other cases of metastases than those listed in the table.

| (PSM) | | | | | | | |
|-------------------------------|--------|--------|-------|--------|-------|--------|---------|
| | C | CW | l | NS | S | С | P Value |
| | N=1354 | % | N=677 | % | N=677 | % | P value |
| Age at diagnosis | | | | | | | 0.944 |
| <49 | 451 | 33.31% | 233 | 34.42% | 237 | 35.01% | |
| 50-69 | 744 | 54.95% | 369 | 54.51% | 363 | 53.62% | |
| ≥70 | 159 | 11.74% | 75 | 11.08% | 77 | 11.37% | |
| Subtype | | | | | | | 0.167 |
| HR+/HER2- | 693 | 51.18% | 334 | 49.34% | 326 | 48.15% | |
| HR+/HER2+ | 273 | 20.16% | 141 | 20.83% | 140 | 20.68% | |
| HR-/HER2+ | 131 | 9.68% | 85 | 12.56% | 77 | 11.37% | |
| HR-/HER2- | 196 | 14.48% | 104 | 15.36% | 109 | 16.10% | |
| Unknown | 55 | 4.06% | 13 | 1.92% | 25 | 3.69% | |
| Race | | | | | | | 0.642 |
| White | 1009 | 74.52% | 487 | 71.94% | 489 | 72.23% | |
| Black | 186 | 13.74% | 95 | 14.03% | 101 | 14.92% | |
| Others | 152 | 11.23% | 93 | 13.74% | 85 | 12.56% | |
| Unknown | 7 | 0.52% | 2 | 0.30% | 2 | 0.30% | |
| Histological type | | | | | | | 0.198 |
| IDC/ILC/Mixed | 1315 | 97.12% | 650 | 96.01% | 648 | 95.72% | |
| Others | 39 | 2.88% | 27 | 3.99% | 29 | 4.28% | |
| Marital status | | | | | | | 0.637 |
| Married | 702 | 51.85% | 360 | 53.18% | 356 | 52.58% | |
| Unmarried | 617 | 45.57% | 298 | 44.02% | 296 | 43.72% | |
| Unknown | 35 | 2.58% | 19 | 2.81% | 25 | 3.69% | |
| T stage | | | | | | | 0.441 |
| T1-2 | 659 | 48.67% | 332 | 49.04% | 330 | 48.74% | |
| T3-4 | 660 | 48.74% | 336 | 49.63% | 329 | 48.60% | |
| Unknown | 35 | 2.58% | 9 | 1.33% | 18 | 2.66% | |
| Grade | | | | | | | 0.073 |
| I; Well differentiated | 74 | 5.47% | 29 | 4.28% | 28 | 4.14% | |
| II; Moderately differentiated | 485 | 35.82% | 235 | 34.71% | 225 | 33.23% | |
| III/IV; Poorly differentiated | 691 | 51.03% | 364 | 53.77% | 390 | 57.61% | |
| Unknown | 104 | 7.68% | 49 | 7.24% | 34 | 5.02% | |
| Median household income | | | | | | | 0 152 |
| (inflation adjusted) | | | | | | | 0.153 |
| <60,000\$ | 332 | 24.52% | 174 | 25.70% | 193 | 28.51% | |
| ≥60,000\$ | 1022 | 75.48% | 503 | 74.30% | 484 | 71.49% | |
| Bone metastases | | | | | | | 0.093 |
| No | 459 | 33.90% | 245 | 36.19% | 248 | 36.63% | |
| Yes | 895 | 66.10% | 430 | 63.52% | 429 | 63.37% | |
| Unknown | 0 | 0.00% | 2 | 0.30% | 0 | 0.00% | |
| Liver metastases | | | | | | | 0.432 |
| | | | | | | | |

Supplement Table 4. Comparison of patient characteristics after propensity score matching (PSM)

| No | 1018 | 75.18% | 510 | 75.33% | 500 | 73.86% | |
|------------------|------|--------|-----|--------|-----|--------|-------|
| Yes | 330 | 24.37% | 164 | 24.22% | 177 | 26.14% | |
| Unknown | 6 | 0.44% | 3 | 0.44% | 0 | 0.00% | |
| Lung metastases | | | | | | | 0.458 |
| No | 1017 | 75.11% | 514 | 75.92% | 499 | 73.71% | |
| Yes | 332 | 24.52% | 157 | 23.19% | 175 | 25.85% | |
| Unknown | 5 | 0.37% | 6 | 0.89% | 3 | 0.44% | |
| Brain metastases | | | | | | | 0.132 |
| No | 1318 | 97.34% | 659 | 97.34% | 648 | 95.72% | |
| Yes | 32 | 2.36% | 14 | 2.07% | 27 | 3.99% | |
| Unknown | 4 | 0.30% | 4 | 0.59% | 2 | 0.30% | |
| | | | | | | | |